These mutations result in the constitutive activation of the EGFR pathway, which promotes cancer cell growth and survival; the EGFR-TKIs exert functions by inhibiting the activity of the EGFR tyrosine kinase, thereby blocking this signaling pathway to inhibit tumor growth [7,8]. The gene discussed is EGFR; the disease is cancer.